bat8010
mAbexperimentalADC
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 10, 2023 (NCT05848466)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2BINDING AGENT
ERBB2 binding agent
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06376136 | Phase 1/Phase 2 (Phase 2) | May 8, 2024 | Biothera |
| NCT05848466 | Phase 1 | Feb 10, 2023 | Biothera |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biothera | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1